AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Gault Cheryl sold $332K of RAPP

Gault Cheryl (Chief Operating Officer) sold 10,000 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $33.19 ($33.04–$33.76, $0.33M total) across 2 trades on 2026-09-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gault Cheryl
Published Oct 1, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Bearish
high confidence
Mentioned
$RAPP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPBearishLow
01

Why it matters

The disclosed sale is modest in size but may be interpreted as a slight negative signal for RAPP's stock.

02

Market read

Provides fresh insider‑sale data; limited trading relevance due to small size.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, reducing the informational value of the transaction.

Relevance 3/10Novelty 3/10Timing: after‑market close 2026‑10‑01

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$RAPPBearishHigh confidence
Context

COO Gault Cheryl sold 10,000 shares for $331,856 via a 10b5‑1 plan, reducing her stake to 139,914 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A C‑suite insider sold shares worth over $300K; such sales are typically viewed as a bearish signal, especially when executed through a pre‑arranged plan.

Market effects

Sector

Minimal; the sale does not affect the broader biotech sector.

Regional

None; the filing is company‑specific.

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity for personal needs and not reflect confidence in the company.

Key entities

  • company
    Rapport Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker RAPP.

  • person
    Gault Cheryl

    Chief Operating Officer of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com